In vitro topo II-DNA complex accumulation and cytotoxicity of etoposide in leukaemic cells from patients with acute myelogenous and chronic lymphocytic leukaemia

Leukemia Research

Volumn 25, Issue 2, 2001, Pages 133-140

  Wang, Yuying ^a   Zhou, Rong ^a   Liliemark, Jan ^a   Gruber, Astrid ^a   Lindemalm, Synnöve ^a   Albertioni, Froudoun ^a   Liliemark, Eva ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cytotoxicity; DNA damage; DNA topo II complex; Etoposide; Leukaemia; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DNA BINDING; DNA DAMAGE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL SURVIVAL; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED;

EID: 0035130687     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00103-X     Document Type: Article

References (39)

1. DNA topoisomerase poisons as antitumor drugs
2. Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity
3. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26)
4. Nucleosomes contain DNA binding proteins that resist dissociation by sodium dodecyl sulfate
5. Cleavage of DNA by mammalian DNA topoisomerase II
6. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II
7. The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4′-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA)
8. Protein measurement with the Folin phenol reagent
9. DNA damage induced by etoposide; a comparison of two different methods for determination of strand breaks in DNA
10. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions
11. Etoposide induced DNA strand-breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukemic cells from patients with AML and CLL
12. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide
13. Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors
14. MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias
15. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells
16. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells
17. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173
18. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA
19. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair [published erratum appears in Cancer Res 1994 Jun 1;54(11):3074]
20. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins
21. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines
22. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II [published erratum appears in Cancer Res 1988 Aug 15;48(16):4716]
23. Drug resistance mechanisms in chronic lymphocytic leukemia
24. Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukemia
25. Topoisomerase II-mediated alterations of K562 drug resistant sublines
26. Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells
27. Interleukin-9 stimulates the proliferation of human myeloid leukemic cells
28. Interleukin-9 in human myeloid leukemia cells
29. Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia
30. Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukemia
31. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report
32. Chronic lymphocytic leukaemia in the Bloemfontein academic hospitals
33. Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators
34. Apoptosis. Its significance in cancer and cancer therapy [published erratum appears in Cancer 1994 Jun 15;73(12):3108]
35. Apoptosis in cancer therapy: crossing the threshold
36. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias
37. Apoptosis and cancer chemotherapy
38. The role of DNA mismatch repair in drug resistance